Chunwoo Lee1, Dalsan You2, Sangjun Yoo2, Cheryn Song2, Bumsik Hong2, Jun Hyuk Hong2, Hanjong Ahn2, Choung-Soo Kim3. 1. Department of Urology, Gyeongsang National University Changwon Hospital, Gyeongsang National University School of Medicine, Changwon, Korea. 2. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 3. Department of Urology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. cskim@amc.seoul.kr.
Abstract
PURPOSE: This study was designed to evaluate and compare the oncological outcomes of patients with pathological T1a (pT1a) small renal cell carcinomas (RCCs) with those with incidental pathological T3a (pT3a) RCCs who have been treated using partial nephrectomy (PN). METHODS: We retrospectively evaluated the records of 1367 consecutive patients who underwent PN for small RCCs (≤4 cm) between 1997 and 2014. The curves for recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method. Cox regression analysis was used to estimate the prognostic significance of each variable. RESULTS: Of the 1367 small RCC patients identified, 1324 (96.8 %) had pT1a lesions and 43 (3.2 %) had pT3a lesions. The median ages of the pT1a and pT3a patients were 53.9 and 58.1 years, respectively. Patients received follow-up for a median of 54 months. The 5- and 10-year RFS rates in patients with pT1a and pT3a RCCs were 98.0 and 95.2 %, and 94.4 and 95.2 %, respectively (P = 0.521). None of the patients with recurrent tumors in the pT3a group have died by the time of the writing of this report. A multivariate Cox proportional hazards model showed that tumor size was a significant predictor of RFS and CSS (P < 0.05). However, pT stage (pT3a vs. pT1a) was not a significant predictor of RFS, CSS, or OS (P = 0.104, P = 0.573, and P = 0.441, respectively). CONCLUSIONS: Our study found that pT3a stage disease following PN for small RCCs (≤4 cm) had similar oncological outcomes to those of pT1a stage.
PURPOSE: This study was designed to evaluate and compare the oncological outcomes of patients with pathological T1a (pT1a) small renal cell carcinomas (RCCs) with those with incidental pathological T3a (pT3a) RCCs who have been treated using partial nephrectomy (PN). METHODS: We retrospectively evaluated the records of 1367 consecutive patients who underwent PN for small RCCs (≤4 cm) between 1997 and 2014. The curves for recurrence-free, cancer-specific, and overall survival were estimated using the Kaplan-Meier method. Cox regression analysis was used to estimate the prognostic significance of each variable. RESULTS: Of the 1367 small RCCpatients identified, 1324 (96.8 %) had pT1a lesions and 43 (3.2 %) had pT3a lesions. The median ages of the pT1a and pT3a patients were 53.9 and 58.1 years, respectively. Patients received follow-up for a median of 54 months. The 5- and 10-year RFS rates in patients with pT1a and pT3a RCCs were 98.0 and 95.2 %, and 94.4 and 95.2 %, respectively (P = 0.521). None of the patients with recurrent tumors in the pT3a group have died by the time of the writing of this report. A multivariate Cox proportional hazards model showed that tumor size was a significant predictor of RFS and CSS (P < 0.05). However, pT stage (pT3a vs. pT1a) was not a significant predictor of RFS, CSS, or OS (P = 0.104, P = 0.573, and P = 0.441, respectively). CONCLUSIONS: Our study found that pT3a stage disease following PN for small RCCs (≤4 cm) had similar oncological outcomes to those of pT1a stage.
Authors: A Breda; S V Stepanian; J Liao; J S Lam; G Guazzoni; M Stifelman; K Perry; A Celia; G Breda; P Fornara; S Jackman; A Rosales; J Palou; M Grasso; V Pansadoro; V Disanto; F Porpiglia; C Milani; C Abbou; R Gaston; G Janetschek; N A Soomro; J de la Rosette; M P Laguna; P G Schulam Journal: J Urol Date: 2007-05-11 Impact factor: 7.450
Authors: Borje Ljungberg; Karim Bensalah; Steven Canfield; Saeed Dabestani; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas Lam; Lorenzo Marconi; Axel S Merseburger; Peter Mulders; Thomas Powles; Michael Staehler; Alessandro Volpe; Axel Bex Journal: Eur Urol Date: 2015-01-21 Impact factor: 20.096
Authors: Karim Bensalah; Allan J Pantuck; Nathalie Rioux-Leclercq; Rodolphe Thuret; Francesco Montorsi; Pierre I Karakiewicz; Nicolas Mottet; Laurent Zini; Roberto Bertini; Laurent Salomon; Arnaud Villers; Michel Soulie; Laurent Bellec; Pascal Rischmann; Alexandre De la Taille; Raffi Avakian; Maxime Crepel; Jean-Marie Ferriere; Jean-Christophe Bernhard; Thierry Dujardin; Frédéric Pouliot; Jérôme Rigaud; Christian Pfister; Baptiste Albouy; Laurent Guy; Steven Joniau; Hendrik van Poppel; Thierry Lebret; Thibault Culty; Fabien Saint; Amnon Zisman; Orit Raz; Hervé Lang; Romain Spie; Andreas Wille; Jan Roigas; Alfredo Aguilera; Bastien Rambeaud; Luis Martinez Piñeiro; Ofer Nativ; Roy Farfara; François Richard; Morgan Roupret; Christian Doehn; Patrick J Bastian; Stefan C Muller; Jacques Tostain; Arie S Belldegrun; Jean-Jacques Patard Journal: Eur Urol Date: 2009-03-31 Impact factor: 20.096
Authors: Tim J van Oostenbrugge; Stephanie G C Kroeze; J L H Ruud Bosch; Harm H E van Melick Journal: World J Urol Date: 2014-09-02 Impact factor: 4.226
Authors: Sangjun Yoo; Dalsan You; In Gab Jeong; Cheryn Song; Bumsik Hong; Jun Hyuk Hong; Hanjong Ahn; Choung-Soo Kim Journal: J Cancer Res Clin Oncol Date: 2017-04-27 Impact factor: 4.553
Authors: Brigitte K Ziegelmueller; Annabel Spek; Bernadett Szabados; Jozefina Casuscelli; Alexander Buchner; Christian Stief; Michael Staehler Journal: Cureus Date: 2019-09-27